NASDAQ:FLXNFlexion Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Flexion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.65 -0.20 (-2.92 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$6.53Now: $6.65▼$6.8850-Day Range$5.53MA: $12.32▼$17.3152-Week Range$5.01Now: $6.65▼$22.98Volume615,954 shsAverage Volume1.06 million shsMarket Capitalization$256.36 millionP/E RatioN/ADividend YieldN/ABeta1.94 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.6 Analyst's Opinion Consensus RatingFlexion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.88, Flexion Therapeutics has a potential upside of 274.1% from its current price of $6.65.Amount of Analyst CoverageFlexion Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesFlexion Therapeutics has received 526 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFlexion Therapeutics has received 347 “underperform” votes. (Add your “underperform” vote.)Community SentimentFlexion Therapeutics has received 60.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote “Outperform” if you believe FLXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFlexion Therapeutics does not currently pay a dividend.Dividend GrowthFlexion Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Flexion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 16.01% of the stock of Flexion Therapeutics is held by insiders.Percentage Held by Institutions83.58% of the stock of Flexion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Flexion Therapeutics are expected to decrease by -56.03% in the coming year, from ($3.07) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Flexion Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Flexion Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.6Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLXN Previous Symbol CUSIPN/A CIK1419600 Webhttp://www.flexiontherapeutics.com/ Phone781-305-7777Debt Debt-to-Equity Ratio27.76 Current Ratio5.40 Quick Ratio4.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$72.96 million Price / Sales3.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.53) per share Price / Book-12.55Profitability EPS (Most Recent Fiscal Year)($3.93) Net Income$-149,770,000.00 Net Margins-205.29% Return on Equity-592.50% Return on Assets-62.47%Miscellaneous Employees272 Outstanding Shares38,550,000Market Cap$256.36 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive FLXN News and Ratings via Email Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FLXN Rates by TradingView Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions How has Flexion Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FLXN stock has decreased by 46.0% and is now trading at $6.65. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Flexion Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flexion Therapeutics. When is Flexion Therapeutics' next earnings date? Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Flexion Therapeutics. How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics Inc (NASDAQ:FLXN) announced its earnings results on Thursday, March, 12th. The specialty pharmaceutical company reported ($0.88) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.95) by $0.07. The specialty pharmaceutical company earned $23.65 million during the quarter, compared to analysts' expectations of $23.50 million. Flexion Therapeutics had a negative net margin of 205.29% and a negative return on equity of 592.50%. View Flexion Therapeutics' earnings history. What guidance has Flexion Therapeutics issued on next quarter's earnings? Flexion Therapeutics updated its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23.7-23.7 million, compared to the consensus revenue estimate of $24.15 million. What price target have analysts set for FLXN? 9 Wall Street analysts have issued twelve-month price objectives for Flexion Therapeutics' shares. Their forecasts range from $17.00 to $36.00. On average, they anticipate Flexion Therapeutics' share price to reach $24.88 in the next year. This suggests a possible upside of 274.1% from the stock's current price. View analysts' price targets for Flexion Therapeutics. Has Flexion Therapeutics been receiving favorable news coverage? News coverage about FLXN stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutFlexion Therapeutics. Are investors shorting Flexion Therapeutics? Flexion Therapeutics saw a decrease in short interest in March. As of March 13th, there was short interest totaling 7,346,700 shares, a decrease of 8.5% from the February 27th total of 8,030,000 shares. Based on an average trading volume of 742,200 shares, the short-interest ratio is currently 9.9 days. Approximately 23.1% of the company's stock are sold short. View Flexion Therapeutics' Current Options Chain. Who are some of Flexion Therapeutics' key competitors? Some companies that are related to Flexion Therapeutics include Zogenix (ZGNX), TG Therapeutics (TGTX), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), NextCure (NXTC), I-Mab (ARQT), Madrigal Pharmaceuticals (MDGL), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Akebia Therapeutics (AKBA), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT) and Phoenix Tree (IMAB). What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Cara Therapeutics (CARA), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Verastem (VSTM), Gilead Sciences (GILD), TherapeuticsMD (TXMD), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO) and Micron Technology (MU). Who are Flexion Therapeutics' key executives? Flexion Therapeutics' management team includes the following people: Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)Mr. David A. Arkowitz, Chief Financial Officer (Age 58)Scott Young, VP of Corp. Communications & Investor Relations What is Flexion Therapeutics' stock symbol? Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN." How do I buy shares of Flexion Therapeutics? Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Flexion Therapeutics' stock price today? One share of FLXN stock can currently be purchased for approximately $6.65. How big of a company is Flexion Therapeutics? Flexion Therapeutics has a market capitalization of $256.36 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe. View additional information about Flexion Therapeutics. What is Flexion Therapeutics' official website? The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/. How can I contact Flexion Therapeutics? Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: How to Calculate Compound Annual Growth Rate (CAGR)
